The PE/PPE family proteins of Mycobacterium tuberculosis: evolution, function, and prospects for tuberculosis control
- PMID: 40599786
- PMCID: PMC12209268
- DOI: 10.3389/fimmu.2025.1606311
The PE/PPE family proteins of Mycobacterium tuberculosis: evolution, function, and prospects for tuberculosis control
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading global health threat, exacerbated by drug resistance and inadequate vaccine efficacy. The PE/PPE protein family, unique to mycobacteria, constitutes ~10% of the Mtb genome and plays critical roles in bacterial physiology, immune evasion, and host-pathogen interactions. This review synthesizes advances in understanding the evolutionary expansion, structural diversity, and functional versatility of PE/PPE proteins, emphasizing their co-evolution with type VII secretion systems (T7SS). We highlight their roles in nutrient acquisition, immune modulation, and pathogenesis, alongside their potential as diagnostic and vaccine targets. Clinical progress in PE/PPE-based vaccines, such as M72/AS01E and ID93/GLA-SE, underscores their promise in combating TB, while challenges in epitope variability and functional redundancy demand innovative strategies. By integrating evolutionary, structural, and immunological insights, this review provides a roadmap for leveraging PE/PPE biology to develop next-generation TB interventions.
Keywords: Mycobacterium tuberculosis; PE/PPE; evolution; outer membrane; porin; vaccine.
Copyright © 2025 Zhang, Dong, Li, Deng and Wang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Role of PE family of proteins in mycobacterial virulence: Potential on anti-TB vaccine and drug design.Int Rev Immunol. 2025;44(4):213-228. doi: 10.1080/08830185.2025.2455161. Epub 2025 Jan 31. Int Rev Immunol. 2025. PMID: 39889764 Review.
-
Tuberculosis Prevention, Control, and Elimination.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30020618 Free Books & Documents.
-
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial.Lancet HIV. 2025 Aug;12(8):e546-e555. doi: 10.1016/S2352-3018(25)00124-9. Epub 2025 Jul 1. Lancet HIV. 2025. PMID: 40614747 Free PMC article. Clinical Trial.
-
Characterization of PPE19 as a novel mediator of Mycobacterium tuberculosis-macrophage interactions.mSphere. 2025 Aug 11:e0003625. doi: 10.1128/msphere.00036-25. Online ahead of print. mSphere. 2025. PMID: 40787981
-
Immune defense and immune evasion in Mycobacterium tuberculosis Infection: Inspirations and challenges for host directed therapy.Microb Pathog. 2025 Oct;207:107914. doi: 10.1016/j.micpath.2025.107914. Epub 2025 Jul 16. Microb Pathog. 2025. PMID: 40681004 Review.
References
-
- W.H.O . Global Tuberculosis Report 2023. Geneva: World Health Organization; (2024).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical